Integrative Physiology/Experimental Medicine |
From the Departments of Cell Biology and Cardiovascular Medicine, Cleveland Clinic, Ohio.
Correspondence to Ephraim Sehayek, MD, 9500 Euclid Ave, NE-10 Cleveland, OH 44195. E-mail sehayee{at}ccf.org
Objective— We examined the effect of ezetimibe, a cholesterol absorption (CA) inhibitor, and genetic determinants of CA on reverse cholesterol transport (RCT) from subcutaneously injected macrophages using a new dual isotope label technique.
Methods and Results— Treatment of C57BL/6J mice with ezetimibe decreased dietary CA by 86% and increased RCT from peripheral tissue macrophages (PTM) by 6-fold (P<0.0001). Moreover, congenic 14DKK mice with a modest 41% decrease in dietary CA displayed a 67% increase in RCT from PTM (P<0.007).
Conclusions— These findings indicate that pharmacological and genetic modifiers of cholesterol absorption are major determinants of reverse cholesterol transport from peripheral tissue macrophages.
Key Words: atherosclerosis cholesterol absorption cholesterol efflux ezetimibe macrophage reverse cholesterol transport
This article has been cited by other articles:
![]() |
M. E. Greenberg, J. D. Smith, and E. Sehayek Moderately Decreased Cholesterol Absorption Rates Are Associated With a Large Atheroprotective Effect Arterioscler Thromb Vasc Biol, November 1, 2009; 29(11): 1745 - 1750. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Rader, E. T. Alexander, G. L. Weibel, J. Billheimer, and G. H. Rothblat The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis J. Lipid Res., April 1, 2009; 50(Supplement): S189 - S194. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |